Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study by Prabhjot Juneja et al.
RESEARCH Open Access
Prostate motion during radiotherapy of prostate
cancer patients with and without application of a
hydrogel spacer: a comparative study
Prabhjot Juneja1,2*, Andrew Kneebone1, Jeremy T. Booth1,2, David I. Thwaites2, Ramandeep Kaur3, Emma Colvill1,4,
Jin A. Ng4, Paul J. Keall4 and Thomas Eade1
Abstract
Background and purpose: The use of a tissue expander (hydrogel) for sparing of the rectum from increased irradiation
during prostate radiotherapy is becoming popular. The goal of this study is to investigate the effect of a tissue expander
(hydrogel) on the intrafraction prostate motion during radiotherapy.
Methods and material: Real time prostate motion was analysed for 26 patients and 742 fractions; 12 patients with and
14 patients without hydrogel (SpaceOAR™). The intra-fraction motion was quantified and compared between the two
groups.
Results: The average (±standard deviation) of the mean motion during the treatment for patients with and without
hydrogel was 1.5 (±0.8 mm) and 1.1 (±0.9 mm) respectively (p < 0.05). The average time of motion >3 mm for patients
with and without hydrogel was 7.7 % (±1.1 %) and 4.5 % (±0.9 %) respectively (p > 0.05). The hydrogel age, fraction
number and treatment time were found to have no effect (R2 < 0.05) on the prostate motion.
Conclusions: Differences in intrafraction motion in patients with hydrogel and without hydrogel were within
measurement uncertainty (<1 mm). This result confirms that the addition of a spacer does not negate the need
for intrafraction motion management if clinically indicated.
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Background
Daily image guidance correcting for interfraction mo-
tion, combined with intensity modulated/volumetric
arc radiotherapy is considered the standard of care for
prostate cancer radiotherapy in many centres [1, 2].
The use of a tissue spacer to move the rectum out of the
high dose field was shown feasible initially with hyaluronic
acid and collagen [3, 4] and now with the commercial
availability of a polyethylene-glycol hydrogel absorbable
water spacer (SpaceOAR™, Augmenix Inc., Waltham, MA)
there has been more widespread utilisation. As radiother-
apy protocols have moved to higher radiation doses and
ultra hypofractionation (>6 Gy per fraction), smaller PTV
margins are being used [5]. Initial results from daily inter-
fraction correction using fiducial markers and a 3 mm
posterior margin were concerning for poor biochemical
control [6], raising the question of intrafraction motion.
Recently, studies have started to utilise intrafraction mo-
tion tracking techniques using Calypso [7] and kilovoltage
intrafraction monitoring (KIM) [8] to mitigate the effect of
prostate motion during treatment delivery. However, the
effect of hydrogel on the prostate motion is not known,
whether the prostate is more stable or less with hydrogel
in place. The application of hydrogel pushes the prostate
towards the fascia, to increase the distance between the
prostate and the anterior rectal wall. The increased mass
is hypothesised to assert lateral pressure that may stabilise
the prostate, buffer from rectal wall movement; or con-
versely it may irritate the rectal wall causing discomfort
and potentially more motion. It is clinically important to
understand the effect of a hydrogel spacer on the prostate
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motion in order to have an evidence based assessment of
the need for intrafraction monitoring, where applicable, or
to quantify the magnitude of the PTV expansion required.
This is important also because intrafraction monitoring
can require expensive additional systems and cause stress
to treatment staff and patient and increase the appoint-
ment times. To the best of the authors’ knowledge, the
effect of hydrogel on intrafraction prostate motion has so
far not been investigated.
Patients in our department enrolled in intrafraction mo-
tion monitoring studies [7, 8] comprised of two patient
populations; those with and those without hydrogel spacer.
The datasets from these studies provide a unique oppor-
tunity to investigate the impact of the hydrogel spacer on
prostate motion. The aim of this study was to quantify the
impact of hydrogel on intrafraction motion.
Material and methods
Patient data
After institutional review board (RNSH) approval, patients
with informed consent were enrolled in 2 prospective clin-
ical trials investigating novel techniques for intrafraction
motion correction [7, 8]. In total 26 patients were available
for analysis. Sixteen patients (503 fractions) were from the
world’s first real-time dynamic multi-leaf collimator (MLC)
tracking trial and were monitored using the Calypso® track-
ing system [7]. Another 10 patients (239 fractions) were
from the world’s first kilo-voltage intra-fraction monitoring
(KIM) trial and were monitored using kV fluoroscopy
imaging [8]. Radiotherapy was delivered using a standard
departmental protocol [9] with all patients simulated with
an empty rectum and a comfortably full bladder. There
were 12 patients (364 fractions) with hydrogel and 14
patients (378 fractions) without hydrogel.
Hydrogel spacer implant
Hydrogel was inserted by one clinician (TE) at the time
of fiducial marker or Calypso beacon implantation, using
a transperineal approach as previously described [10].
Treatment imaging
In the case of patients in MLC tracking trial, the real-time
position of the prostate was measured using the Calypso®
tracking system [7]. This uses implanted electromagnetic
transponder-based markers [11]. Each patient had three
electromagnetic markers implanted in the prostate gland.
For the patients in the KIM trial, kV fluoroscopy was used
to monitor, in real-time, the 3D position of three radio-
opaque markers implanted into the prostate target [8, 12].
In both the trials, the location of the centroid of the im-
planted markers throughout treatment was used to calcu-
late the intra-fraction prostate motion.
Measure of prostate motion
Prostate motion was calculated using the probability of
vector displacement. This plot provides a descriptive dis-
tribution of probabilities of various motion ranges [13].
The probability of vector displacement provides a detailed
representation of the motion. For each prostate motion
trajectory, motion was quantified by the mean of the
largest x % of the vector displacements; x was investigated
for 10, 20, 30, 40 and 50 %. For simplicity of presentation
only results for 20 and 50 % are reported. Also, a mean of
the vector displacements during the fractions was calcu-
lated. Previously in the literature, Langen et al. [14] have
defined and used the fraction of time the prostate dis-
placements are >3, >5, >7, and >10 mm; and Haisen et al.
[15] have defined and investigated R95, which represents
that the vector displacement is less than R95 during 95
percentage of the monitoring time. These metrics were
also evaluated.
Analysis
The probability of vector displacements for patients
with and without hydrogel spacer was compared. Box
plots were used to present and compare the differences
in the motion metrics between these two groups. The
Wilcoxon rank sum test was used as a test of the statis-
tical significance of the differences and the Bonferroni
correction [16] was used to counteract the significance
threshold for multiple comparisons. Where several hy-
potheses are tested, the chance of obtaining at least one
“statistically significant” result increases (even if all
hypotheses are true) and therefore a correction method
is needed to control for false positives. In addition, the
effect of hydrogel age on prostate motion was also
investigated.
As a secondary analysis, other factors that might
affect prostate motion were also studied. The impact of
treatment time and fraction number on motion was
undertaken. The correlations were evaluated through
the Pearson’s correlation, and coefficients of determin-
ation (R2) have been reported. These were calculated for
all the available fractions (including patient with and
without hydrogel), and for each patient, over their frac-
tions. The difference between the prostate position at the
start and end of the treatment has been used previously to
describe intrafraction motion [17–19]. This hypothesis
that the intra-fraction prostate motion range is equivalent
to the difference between the prostate position at the start
and end of the treatment was investigated using the
Bland-Altman analysis [20]. The Bland-Altman analysis is
a method to evaluate agreement between two measure-
ment techniques. The prostate motion range of a fraction
was defined by the maximum displacement between any
two time points during the fraction.
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Results
The probability of prostate motion (vector displacement)
for patients with and without hydrogel is shown in Fig. 1.
For the displacements less than 4 mm, corresponding
mean probabilities of prostate motion are slightly higher
for patients with hydrogel than without hydrogel. Another
thing to note in Fig. 1 is that for larger displacement
(>10 mm), the data is sparse (less than 5 non-zero values
per data point) and therefore any conclusion could not be
drawn regarding the effect of hydrogel in this motion
range. The quantification of the motion using the prede-
fined motion metrics is shown in Fig. 2. The results for
largest 10, 20, 30, 40 and 50 % motion measures were
similar. As mentioned earlier, for simplicity, results for
20 and 50 % only are reported. In the calculation of dis-
placement greater than 3, 5, 7 and 10 mm metrics only
the >3 mm threshold had more than 30 fractions in
each of the groups with non-zero values. As such the
other three >5 mm, >7 mm, and >10 mm were not con-
sidered further. The mean values (±standard deviation)
of Langen >3 mm for patients with and without hydro-
gel were 7.7 % (±1.1 %) and 4.5 % (±0.9 %) respectively
(p > 0.05). For all the metrics used in this study, except
Langen’s, the motion was significantly higher (p < 0.05)
in patients with hydrogel, however it should be noted
the mean absolute differences were less than 0.5 mm
which is similar to the measurement uncertainty.
Effect of hydrogel age, fraction number, treatment time
on prostate motion
No correlation (R2 < 0.05) was found between hydrogel
age and prostate motion, for each of the motion metrics,
across all the available fractions. The distribution of a
motion metric, mean of the largest 50 % with respect to
hydrogel age is presented in Fig. 3a. Furthermore, when
analysis was performed for individual patients’ fractions,
for each of the motion metrics, correlation was weak
(R2 < 0.20). Similarly, fraction number and treatment
time were found to be not correlated (R2 < 0.05) to the
prostate motion, see Fig. 3b and c.
Relationship between prostate motion range and
difference in treatment start and end positions
The motion metrics, mean of the largest 20 % and 50 %,
and Haisen R95, had moderate correlation (R
2 ≈ 0.50) with
the difference in prostate positions between start and end
of the treatment. The prostate motion range was also
found to have moderate correlation (R2 ≈ 0.51) with the
difference in prostate positions between start and end of
the treatment, see Fig. 3d. In the case of analysis of indi-
vidual patients’ fractions, mean (range) correlation was
0.51 (0.05–0.91). The Bland-Altman analysis showed
that the difference between the motion range and the
differences in start and end positions were significantly
different (p < 0.0001), the mean difference (range) was
1.7 mm (0.1–13.7 mm).
Discussion
This study investigated for the first time the effect of
hydrogel spacer on intrafraction prostate motion through-
out the course of treatment. The mean differences between
the motion metrics in the patient groups with and without
hydrogel were found to be of the order of measurement
uncertainty (≈0.5 mm) though if anything, greater intra-
fraction motion was seen in the hydrogel group. In line
with this finding, Pinkawa et al. [21] have recently shown
that inter-fraction prostate position variability is similar in
patients who are treated with and without the hydrogel,
Fig. 1 Probability of prostate motion (vector displacement) in the groups with hydrogel and without hydrogel. The central line is the mean probability.
The shaded region shows mean ± 1 standard deviation
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with the motion modestly higher in the hydrogel group. It
should be noted that their study used only two time points,
one at the planning of treatment and another one in the
last week of treatment while our study analysed real-time
prostate motion data over the entire course of treatments.
This study has shown that there is minimal clinical dif-
ference in intrafraction motion in patients with and with-
out hydrogel spacer. Furthermore, the age of the hydrogel
spacer along with fraction number and treatment time
were found to have no effect on the intra-fraction prostate
motion (R2 < 0.05). This may partly be due to the low
intrafraction motion in both groups with over 95 % of the
fractions had mean motion less than 3 mm.
All of our patients were simulated with an empty rec-
tum and comfortably full bladder but not specifically
placed on a low residue diet. Intermittent cone beam CT
was also used during treatment to aid the treatment staff
with feedback to patients regarding bladder and rectal
Fig. 2 Comparison of vector displacement metrics in the groups with hydrogel and without hydrogel. On each box, the central mark is the median,
the edges of the box are the 25th and 75th percentiles, the whiskers extend to maximum± 2.7 standard deviation (~99 % coverage)
a) b)
c) d)
Fig. 3 Correlation between prostate motion, mean (mm) of largest 50 % motion, and a. hydrogel age; b. fraction number; and c. treatment time.
d. Correlation between differences in treatment start and end positions and prostate motion range. Note: Error bars in a. and b. represents
mean ± standard deviation of all available fractions
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size. All patients were treated with a volumetric arc tech-
nique, which reflects beam on times more representative
of a modern prostate cancer cohort, as compared to the
original intrafraction motion data [14] that used a step and
shoot technology. This can be seen in Fig. 3c. where the
majority of the treatment beam on times were less than
3 min. Interestingly even in our patients with longer beam
on times (>3 min, n = 74) due to hypofractionation, intra-
fraction motion was still low (mean motion: 0.5–2.7 mm).
Figure 3 also shows a comparison of continuous real-
time tracking and a surrogate of intrafraction motion using
the start and end of RT marker positions. This later tech-
nique has been used previously to describe intrafraction
motion [17–19]. Although pre and post treatment dis-
placement can give some information of the intra-fraction
motion, our comparison shows this is not adequate. This
was also shown by Noel et al. [22] using a Calypso® system.
This technique commonly under-represents motion and in
some cases can over-represent it. In the first case the pros-
tate may have moved away from the initial setup for most
of the treatment but near the end of RT returned closer to
the pre RT position. In this case the cumulative dose
impact will be significantly greater than the pre and post
position data shows. The opposite may also occur, al-
though less commonly, when the prostate is relatively
stable for most of the treatment, but moves near the end of
the beam on.
This study also found that the fraction number and
treatment time have no effect on the intra-fraction pros-
tate motion (R2 < 0.05). Kotte et al. [23] also did not find
correlation between the intra-fraction prostate motion
and the fraction number. Langen et al. [14] in their
study compared the prostate motions in the first and last
five treatment fractions of the patients and found non-
significant differences. All the available fractions, with
and without hydrogel were used in our analysis while
these past studies only had patients without hydrogel.
Previously, correlation between prostate motion and ob-
servation time (>5 min) has been shown [13, 14, 23, 24].
It should be noted that these studies considered intensity
modulated radiotherapy (IMRT) and that the total time
was not just the ‘actual’ treatment time (i.e. the start of
first field to the end of last field) but also included the
time between setup and beam on [13, 14, 24]. In com-
parison, the patients in the current study were treated
with volumetric arc therapy and the observation time
used was the ‘actual’ treatment time.
A study of prostate IMRT for a 2 Gy fraction has re-
ported actual treatment times between 3.8 and 5.9 min de-
pending on the number of fields (5–9 fields) [25]. In the
current study, the analysis of fractions (n = 71) with hydro-
gel and treatment time greater than 3 min (3.06–7.52 min)
found that their motion was not significantly different
(p > 0.05) from the motion in fractions with times less
than 3 min. Also, in these large fractions, the correla-
tions between the motion metrics and treatment time
was very low (R2 < 0.05).
Intrafraction motion is thought to be predominantly
due to rectal motion, bladder filling, respiration, and/or
patient movement [26]. It was unknown previously what
impact a water based tissue expander (hydrogel) would
have on motion, with the potential it could be decreased
due to “fixation” of the prostate because hydrogel pushes
prostate towards the fascia, or increased due to rectal wall
irritability in the presence of hydrogel. It is reassuring that
our study has confirmed no detriment with hydrogel in
this respect. It is also important for clinicians using hydro-
gel to continue to consider intrafraction motion.
Conclusions
The effect of addition of a hydrogel spacer on intrafraction
prostate motion was examined and shown to be within
measurement uncertainty (<1 mm) and felt to be clinically
insignificant. Therefore, the clinical need for intrafraction
motion management should be evaluated independently,
irrespective of hydrogel presence or not.
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